Canoe Financial LP Sells 3,375 Shares of Elevance Health, Inc. $ELV

Canoe Financial LP decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 0.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 367,287 shares of the company’s stock after selling 3,375 shares during the period. Canoe Financial LP’s holdings in Elevance Health were worth $107,523,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Sei Investments Co. raised its position in Elevance Health by 7.7% in the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after purchasing an additional 11,745 shares during the last quarter. Glenview Trust co boosted its stake in Elevance Health by 41.5% in the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after purchasing an additional 475 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Elevance Health by 6.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after purchasing an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Elevance Health by 5.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after buying an additional 2,012 shares in the last quarter. Finally, Quantinno Capital Management LP increased its stake in shares of Elevance Health by 111.8% in the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock valued at $17,080,000 after buying an additional 23,180 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ELV has been the topic of several research reports. The Goldman Sachs Group upped their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Robert W. Baird raised their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Sanford C. Bernstein boosted their target price on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Morgan Stanley upped their target price on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. Finally, Jefferies Financial Group decreased their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $416.11.

Elevance Health Trading Down 0.1%

Shares of ELV opened at $394.86 on Monday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $426.98. The firm has a market capitalization of $85.75 billion, a PE ratio of 16.80, a price-to-earnings-growth ratio of 2.24 and a beta of 0.67. The stock’s fifty day simple moving average is $383.03 and its 200-day simple moving average is $349.14.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts predict that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Nephron Research’s FY2027 EPS estimate of $28.95 is above the current consensus, signaling stronger expected earnings growth ahead.
• Positive Sentiment: The firm also projected FY2026 EPS of $25.73, which supports a solid near-term earnings profile for Elevance Health.
• Neutral Sentiment: Nephron Research provided quarterly estimates across 2026 and 2027, including Q2 2026 EPS of $6.15 and Q1 2027 EPS of $13.01, but the release was primarily an estimates update rather than a new business announcement.
• Neutral Sentiment: An article previewing Elevance Health’s Q2 2026 earnings suggests investors are positioning ahead of the next report, but no actual results were released in these items.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.